Home Business Wire Transphorm Announces Record Fiscal 2022 Full Year Revenue of $24.1 Million

Transphorm Announces Record Fiscal 2022 Full Year Revenue of $24.1 Million

– an 89% Year-Over-Year Increase as Fiscal 2022 Fourth Quarter Revenue Increased 103% 

Company to Host a Webcast Today at 5:00 p.m. ET to Review the Quarterly Results and Provide a Business Update

GOLETA, Calif.–(BUSINESS WIRE)–Transphorm, Inc. (NASDAQ: TGAN)—an innovative design pioneer and global supplier of efficient, high-reliability, high-performance gallium nitride (GaN) power conversion products, announced today financial results for the Company’s 2022 fiscal fourth quarter and the fiscal year ended March 31, 2022.

Fiscal Fourth Quarter and Recent Highlights

  • Achieved up listing of Transphorm’s common stock to the NASDAQ under the ticker symbol TGAN.
  • Full year FY22 revenue increased 89% year-over-year to a record $24.1 million due to strong growth in product revenue based on prior targeted investments in designs for a broader market.
  • FY22 product revenue increased sequentially for the ninth consecutive quarter to a record of over $4 million, a 190% sequential increase when compared to Q4 FY21.
  • Secured largest SuperGaN® high-power Gen IV FET production order for the Company to date for over 500,000 units of 3kW class power supplies. The magnitude of this order clearly demonstrates Transphorm’s continuing leadership in design innovation and manufacturing reliability of high-power GaN.
  • Secured laptop adapter design-win from a Tier 1 Fortune 100 company, including an initial purchase order of 50,000 units of SuperGaN® Gen IV 240 mohm class FETs. These FETs provide higher efficiency for 65W fast-charging adapter applications versus competing e-mode GaN FETs that require a larger 150 mohm device for similar applications. As a result, these Transphorm SuperGaN® FETs allow our customers to do more with less.
  • Secured pre-production POs from ODMs for large Asia mobile phone (65W) and leading WW e-retailer (140W) projects
  • Announced the first 99% efficient power switching demonstration from a 1200V GaN power transistor prototype, demonstrating Transphorm’s cutting-edge innovation in high-power GaN.
  • Cash and equivalents as of March 31, 2022 were $34.0 million.

Primit Parikh, Transphorm’s President and Co-founder, commented, “We are excited to continue to deliver strong revenue growth, having achieved our 9th consecutive quarter of record product revenue. We also reaffirmed our leadership in high-power GaN by securing our largest order to date for over a half-million 3kW class GaN products.

Dr. Parikh continued, “The demand for our GaN solutions is strong, driven by our products’ unique, easy to interface architecture, world leading GaN product portfolio with a broad range of power capabilities from 45W to 5kW, and leading performance with field reliability. With a strong backlog in place, our current focus is on managing supply chain constraints, expanding our manufacturing capacity, and continuing to grow our ecosystem of solution partners”.

Cameron McAulay, CFO of Transphorm, stated “During the 2022 fiscal year we completed an uplisting to the NASDAQ, dramatically improving the Company’s liquidity. Along with the additional capital we raised in fiscal Q3 of 2022, this provides expanded operational flexibility in support of our future anticipated growth.”

Fiscal 2022 Fourth Quarter and Full Year Financial Results

Revenue for the 2022 fiscal fourth quarter was $4.93 million, compared to $4.6 million in the 2022 fiscal third quarter ended December 31, 2021 and $2.4 million in the 2021 fiscal fourth quarter ended March 31, 2021. Revenue for the quarter reflected yet another record in product sales from ramping shipments of GaN devices for a broad range of power conversion applications, with a 10% sequential increase from the prior quarter. For the full fiscal year 2022, product sales increased 189% as compared to full fiscal year 2021.

Operating expenses on a GAAP basis were $5.6 million in the 2022 fiscal fourth quarter, compared to $5.4 million in the prior quarter and $5.2 million in the 2021 fiscal fourth quarter. 2022 fiscal fourth quarter operating expenses consisted of R&D expenses of $1.6 million and SG&A expenses of $4.0 million. On a non-GAAP basis, operating expenses in the 2022 fiscal fourth quarter were $4.6 million, compared with non-GAAP operating expenses of $4.4 million in the prior quarter and $4.5 million in the 2021 fiscal fourth quarter.

GAAP net profit (loss) for the 2022 fiscal fourth quarter was ($5.0) million, or ($0.09) per share, compared to GAAP net loss of ($4.2) million, or ($0.08) per share, in the prior quarter, and a GAAP net loss of ($6.6) million, or ($0.16) per share, in the 2021 fiscal fourth quarter. On a non-GAAP basis, net loss for the 2022 fiscal fourth quarter was ($4.0) million, or ($0.08) per share, compared to non-GAAP net loss of ($4.3) million, or ($0.09) per share, in the prior quarter, and a non-GAAP net loss of ($5.2) million, or ($0.13) per share, in the 2021 fiscal fourth quarter.

Cash and equivalents as of March 31, 2022 were $34 million, compared to $9.5 million at March 31, 2021.

Webcast

Transphorm will host a webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the Company’s 2022 fiscal fourth quarter and the fiscal year ended March 31, 2022 results and provide a business update. The webcast can be accessed at: https://event.on24.com/wcc/r/2947335/9EA3AFF729C086351F33CF46EFE76B59

Investors and analysts may also join the conference call by dialing: 1 (888) 330-2446 or 1 (240) 789-2732 and providing the conference ID: 8060388.

A replay and the supporting presentation materials will be available on the day of the conference call and for approximately 90 days on the Investor Relations section of the Company’s website. Additionally, a telephone replay of the conference call will be available after the conclusion of the call and through May 31, 2022. The telephone replay can be accessed by dialing +1-800-770-2030 and entering the conference ID: 8060388.

About Transphorm

Transphorm, Inc., a global leader in the GaN revolution, designs and manufactures high performance and high reliability GaN semiconductors for high voltage power conversion applications. Having one of the largest Power GaN IP portfolios of more than 1,000 owned or licensed patents, Transphorm produces the industry’s first JEDEC and AEC-Q101 qualified high voltage GaN semiconductor devices. The Company’s vertically integrated device business model allows for innovation at every development stage: design, fabrication, device, and application support. Transphorm’s innovations are moving power electronics beyond the limitations of silicon to achieve over 99% efficiency, 40% more power density and 20% lower system cost. Transphorm is headquartered in Goleta, California and has manufacturing operations in Goleta and Aizu, Japan. For more information, please visit www.transphormusa.com. Follow us on Twitter @transphormusa and WeChat @ Transphorm_GaN.

Non-GAAP Financial Measures

This press release includes and makes reference to certain non-GAAP financial measures. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

Transphorm believes that the presentation of non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company’s financial condition and results of operations. Transphorm believes that these non-GAAP financial measures provide additional insight into Transphorm’s ongoing performance and core operational activities and has chosen to provide these measures for more consistent and meaningful comparison between periods. These measures should only be used to evaluate Transphorm’s results of operations in conjunction with the corresponding GAAP measures. The non-GAAP results exclude the effect of stock-based compensation, depreciation, amortization, change in fair value of promissory note and other income in joint venture.

A reconciliation between GAAP and non-GAAP financial results is provided in the financial statements portion of this press release.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning industry acceptance of GaN technology, the Company’s ability to manage supply chain constraints, expand its manufacturing capacity, and grow its ecosystem of solution partners, and the Company’s pipeline and future anticipated growth. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: risks related to Transphorm’s operations, such as additional financing requirements and access to capital; competition; the ability of Transphorm to protect its intellectual property rights; and other risks set forth in the Company’s filings with the Securities and Exchange Commission. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Transphorm, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

 

March 31, 2022
(unaudited)

 

December 31, 2021
(unaudited)

 

March 31, 2021
(audited)

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

$

33,435

 

 

$

40,467

 

 

$

9,500

 

Restricted cash

 

500

 

 

 

500

 

 

 

 

Accounts receivable

 

2,632

 

 

 

2,489

 

 

 

1,618

 

Inventory

 

6,330

 

 

 

5,956

 

 

 

2,223

 

Prepaid expenses and other current assets

 

1,750

 

 

 

1,249

 

 

 

953

 

Total current assets

 

44,647

 

 

 

50,661

 

 

 

14,294

 

Property and equipment, net

 

1,796

 

 

 

1,897

 

 

 

1,360

 

Goodwill

 

1,180

 

 

 

1,250

 

 

 

1,302

 

Intangible assets, net

 

617

 

 

 

691

 

 

 

914

 

Investment in joint venture

 

143

 

 

 

61

 

 

 

 

Other assets

 

263

 

 

 

282

 

 

 

274

 

Total assets

$

48,646

 

 

$

54,842

 

 

$

18,144

 

 

 

 

 

 

 

Liabilities and stockholders’ equity (deficit)

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable and accrued expenses

$

3,626

 

 

$

4,749

 

 

$

3,140

 

Deferred revenue

 

308

 

 

 

267

 

 

 

505

 

Development loan

 

 

 

 

 

 

 

10,000

 

Revolving credit facility

 

180

 

 

 

368

 

 

 

10,150

 

Unfunded commitment in joint venture

 

 

 

 

 

 

 

1,866

 

Accrued payroll and benefits

 

1,171

 

 

 

1,239

 

 

 

1,410

 

Total current liabilities

 

5,285

 

 

 

6,623

 

 

 

27,071

 

Revolving credit facility

 

12,000

 

 

 

12,000

 

 

 

 

Promissory note

 

 

 

 

 

 

 

16,128

 

Total liabilities

 

17,285

 

 

 

18,623

 

 

 

43,199

 

Commitments and contingencies

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

 

 

Common stock

 

5

 

 

 

5

 

 

 

4

 

Additional paid-in capital

 

211,190

 

 

 

210,841

 

 

 

144,201

 

Accumulated deficit

 

(178,638

)

 

 

(173,639

)

 

 

(168,403

)

Accumulated other comprehensive loss

 

(1,196

)

 

 

(988

)

 

 

(857

)

Total Stockholders’ equity (deficit)

 

31,361

 

 

 

36,219

 

 

 

(25,055

)

Total liabilities and stockholders’ equity (deficit)

$

48,646

 

 

$

54,842

 

 

$

18,144

 

Transphorm, Inc.

Condensed Consolidated Statements of Operations

(in thousands except share and per share data)

 

 

Three Months Ended

 

Twelve Months Ended

 

March 31, 2022

(unaudited)

 

December 31, 2021

(unaudited)

 

March 31, 2021

(audited)

 

March 31, 2022

(unaudited)

 

March 31, 2021

(unaudited)

Revenue, net

$

4,927

 

 

$

4,604

 

 

$

2,425

 

 

$

24,050

 

 

$

12,696

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

3,789

 

 

 

3,935

 

 

 

1,788

 

 

 

12,530

 

 

 

7,015

 

Research and development

 

1,632

 

 

 

1,609

 

 

 

1,780

 

 

 

6,655

 

 

 

5,898

 

Sales and marketing

 

1,047

 

 

 

976

 

 

 

663

 

 

 

3,535

 

 

 

2,319

 

General and administrative

 

2,917

 

 

 

2,852

 

 

 

2,733

 

 

 

11,226

 

 

 

9,969

 

Total operating expenses

 

9,385

 

 

 

9,372

 

 

 

6,964

 

 

 

33,946

 

 

 

25,201

 

Loss from operations

 

(4,458

)

 

 

(4,768

)

 

 

(4,539

)

 

 

(9,896

)

 

 

(12,505

)

Interest expense

 

181

 

 

 

187

 

 

 

187

 

 

 

792

 

 

 

758

 

Loss in joint venture

 

677

 

 

 

712

 

 

 

1,468

 

 

 

3,971

 

 

 

6,885

 

Changes in fair value of promissory note

 

 

 

 

 

 

 

699

 

 

 

(605

)

 

 

2,093

 

Other income, net

 

(317

)

 

 

(1,503

)

 

 

(314

)

 

 

(3,819

)

 

 

(1,940

)

Loss before tax expense

 

(4,999

)

 

 

(4,164

)

 

 

(6,579

)

 

 

(10,235

)

 

 

(20,301

)

Tax expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(4,999

)

 

$

(4,164

)

 

$

(6,579

)

 

$

(10,235

)

 

$

(20,301

)

Net loss per share – basic and diluted

$

(0.09

)

 

$

(0.08

)

 

$

(0.16

)

 

$

(0.22

)

 

$

(0.56

)

Weighted average common shares outstanding – basic and diluted

 

53,343,862

 

 

 

49,147,630

 

 

 

40,274,660

 

 

 

46,056,331

 

 

 

36,555,353

 

Transphorm, Inc.

Reconciliation of GAAP and Non-GAAP Financial Information (unaudited)

(in thousands except share and per share data)

 

 

Three Months Ended

 

Twelve Months Ended

 

March 31,

2022

 

December

31,2021

 

March 31,

2021

 

March 31,

2022

 

March 31,

2021

GAAP net loss

$

(4,999

)

 

$

(4,164

)

 

$

(6,579

)

 

$

(10,235

)

 

$

(20,301

)

Adjustments:

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

758

 

 

 

848

 

 

 

513

 

 

 

2,614

 

 

 

1,906

 

Depreciation

 

147

 

 

 

142

 

 

 

123

 

 

 

546

 

 

 

500

 

Amortization

 

74

 

 

 

74

 

 

 

74

 

 

 

296

 

 

 

296

 

Changes in fair value of promissory note

 

 

 

 

 

 

 

699

 

 

 

(605

)

 

 

2,139

 

Other income (1)

 

 

 

 

(1,222

)

 

 

 

 

 

(2,677

)

 

 

 

Total adjustments to GAAP net loss

 

979

 

 

 

(158

)

 

 

1,409

 

 

 

174

 

 

 

4,841

 

Non-GAAP net loss

$

(4,020

)

 

$

(4,322

)

 

$

(5,170

)

 

$

(10,061

)

 

$

(15,460

)

GAAP net loss per share – basic and diluted

$

(0.09

)

 

$

(0.08

)

 

$

(0.16

)

 

$

(0.22

)

 

$

(0.54

)

Adjustment

 

0.01

 

 

 

(0.01

)

 

 

0.03

 

 

 

 

 

 

0.12

 

Non-GAAP net loss per share – basic and diluted

$

(0.08

)

 

$

(0.09

)

 

$

(0.13

)

 

$

(0.22

)

 

$

(0.42

)

Weighted average common shares outstanding – basic and diluted

 

53,343,862

 

 

 

49,147,630

 

 

 

40,274,660

 

 

 

46,056,331

 

 

 

36,555,353

 

(1) Other income consists of $1.2 million gain upon the conversion of the Yaskawa Note for the three months ended December 31, 2021 and $1.5 million gain upon termination of the joint venture agreement between Fujitsu Semiconductor Limited and Transphorm Aizu for the three months ended September 30, 2021.

 

Three Months Ended

 

Twelve Months Ended

 

March 31,
2022

 

December
31, 2021

 

March 31,

2021

 

March 31,

2022

 

March 31,

2021

GAAP operating expenses

$

5,596

 

$

5,437

 

$

5,176

 

$

21,416

 

$

18,186

Adjustments:

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

715

 

 

796

 

 

475

 

 

2,453

 

 

1,789

Depreciation

 

147

 

 

142

 

 

123

 

 

546

 

 

500

Amortization

 

74

 

 

74

 

 

74

 

 

296

 

 

296

Total adjustments to GAAP operating expenses

 

936

 

 

1,012

 

 

672

 

 

3,295

 

 

2,585

Non-GAAP operating expenses

$

4,660

 

$

4,425

 

$

4,504

 

$

18,121

 

$

15,601

Transphorm, Inc.

Consolidated Statements of Cash Flows (unaudited)

(in thousands)

 

 

Twelve Months Ended March 31,

 

2022

 

2021

Cash flows from operating activities:

 

 

 

Net loss

$

(10,235

)

 

$

(20,301

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Inventory write-off

 

196

 

 

 

273

 

Depreciation and amortization

 

842

 

 

 

796

 

Provision for doubtful accounts

 

 

 

 

62

 

Licensing revenue from a related party

 

(8,000

)

 

 

(5,000

)

Stock-based compensation

 

2,614

 

 

 

1,906

 

Interest cost

 

107

 

 

 

758

 

Gain on promissory note conversion

 

(1,222

)

 

 

 

Gain on sale of equipment

 

 

 

 

(40

)

Loss in joint venture

 

2,516

 

 

 

6,885

 

Changes in fair value of promissory note

 

(605

)

 

 

2,093

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

(1,014

)

 

 

(267

)

Inventory

 

(4,303

)

 

 

(1,411

)

Prepaid expenses and other current assets

 

(297

)

 

 

428

 

Other assets

 

11

 

 

 

214

 

Accounts payable and accrued expenses

 

236

 

 

 

(132

)

Deferred revenue

 

(197

)

 

 

505

 

Accrued payroll and benefits

 

(239

)

 

 

334

 

Net cash used in operating activities

 

(19,590

)

 

 

(12,897

)

Cash flows from investing activities:

 

 

 

Purchases of property and equipment

 

(742

)

 

 

(222

)

Investment in joint venture

 

(4,526

)

 

 

(6,768

)

Net cash used in investing activities

 

(5,268

)

 

 

(6,990

)

Cash flows from financing activities:

 

 

 

Proceeds from sale of equipment

 

 

 

 

4

 

Proceeds from stock option exercise

 

221

 

 

 

16

 

Proceeds from issuance of common stock

 

49,773

 

 

 

14,596

 

Proceeds from exercise of warrants

 

272

 

 

 

 

Payment for taxes related to net share settlement of restricted stock units

 

(768

)

 

 

 

Net cash provided by financing activities

 

49,498

 

 

 

14,616

 

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

 

(205

)

 

 

123

 

Net increase in cash, cash equivalents and restricted cash

 

24,435

 

 

 

(5,148

)

Cash, cash equivalents and restricted cash at beginning of period

 

9,500

 

 

 

14,648

 

Cash, cash equivalents and restricted cash at end of period

$

33,935

 

 

$

9,500

 

Contacts

Investor Contacts:
David Hanover or Jack Perkins

KCSA Strategic Communications

transphorm@kcsa.com

Company Contact:
Cameron McAulay

Chief Financial Officer

1-805-456-1300 ext. 140

cmcaulay@transphormusa.com

Se questo articolo ti è piaciuto e vuoi rimanere sempre informato sulle novità tecnologiche
css.php